Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy

Cancer immunology research

Volumn 1, Issue 6, 2013, Pages 373-377

  Johnson, Douglas B ^a   Wallender, Erika K ^a   Cohen, Daniel N ^a   Likhari, Sunaina S ^a   Zwerner, Jeffrey P ^a   Powers, Jennifer G ^a   Shinn, Lisa ^a   Kelley, Mark C ^a   Joseph, Richard W ^a   Sosman, Jeffrey A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anti PD 1; immunotherapy; Melanoma; vemurafenib

Indexed keywords

AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; IMIQUIMOD; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; NIVOLUMAB; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; SULFONAMIDE; VEMURAFENIB;

ADULT; ANAPHYLAXIS; ANTAGONISTS AND INHIBITORS; CASE REPORT; CHEMICALLY INDUCED; DRUG ERUPTIONS; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

ADULT; AMINOQUINOLINES; ANAPHYLAXIS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ERUPTIONS; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; INDOLES; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS; SULFONAMIDES;

EID: 85006320672     PISSN: None     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-13-0092     Document Type: Article

References (0)